CIM: Due to the fact this is a new industry and there are no historical comps, investors use management team experience as a key metric when investing, what past skillsets and experiences does your management team have to give investors confidence that HLIX will be successful?
HLIX: As a management team we have successfully invested and operated across the Middle East, Eastern Europe, and Africa. There are no harder training grounds for an executive team. Further, we have almost always done so by investing our own capital first, which gives us a very focused perspective, and we personally lead in every aspect of entrepreneurship from ideation, to strategy formation, to execution, to exit.
CIM: With so much great news lately it is difficult to know where to start or how far back to go while also trying to stay within time constraints. Let’s start off with information that every investor looks at first. The numbers! According to your stock’s OTC page (CLICK HERE), your current market cap is $47M and there are only about 30.4M shares outstanding. Your December year end report has 2017 revenue at $4M (>90% increase over 2016) … you March 31, 2018 financials show your Q1 revenue at $1.1M – already trending towards 2018 being materially greater than 2017. To the extent that you can, can investors expect to see this trend of increased revenues to continue into Q2 and beyond? Of the shares outstanding, can you advise what % are held by key stakeholders such as insiders?
HLIX: The OTC page shows only common stock outstanding. As we’ve disclosed in our 10-K’s and 10-Q’s there are also almost 15 million preferred shares and common stock warrants, so prior to the BioTrack merger we had approximately 50M shares outstanding fully diluted. That number is nearly double now, as we disclosed in our 8-k following the merger. So the fully diluted market cap is approximately $150MM. Collectively insiders hold a meaningful majority of the shares outstanding, so we are all incentivized to make this work out well.
With the BioTrack results consolidated into Helix we are a $12MM company on a backward–looking basis. The merger closed at the start of June, so in 2018 we will have 7 months of BioTrack results in our 2018 financial statements.
CCIM: Growing revenues, significant positive transformation and relationships, low number of outstanding shares … I think we can agree it’s not by chance were shining the spotlight on your company at this time. Helix is also looking at an international presence … can you expand on this aspect of your business and specifically Helix’s recently announced partnership with Timeless Herbal Care (“Timeless”), a leading Jamaican cannabis grower?
117